Initiation of dapagliflozin and treatment-emergent fractures

Diabetes, Obesity and Metabolism

Volumn 20, Issue 4, 2018, Pages 1070-1074

  Toulis, Konstantinos A ^a,b   Bilezikian, John P ^c   Thomas, G Neil ^a   Hanif, Wasim ^d   Kotsa, Kalliopi ^e   Thayakaran, Rasiah ^a   Keerthy, Deepiksana ^a   Tahrani, Abd A ^a,f,g   Nirantharakumar, Krishnarajah ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b 424 General Army Hospital   (Greece)

^c Columbia University ^*  (United States)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f Birmingham Women's Hospital NHS Foundation Trust   (United Kingdom)

^g BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

fracture risk assessment; practice policy related issues; sodium glucose co transporter inhibitors; statistical methods; therapeutics

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FRACTURE; FRAGILITY FRACTURE; GENDER; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SPINE FRACTURE; WRIST FRACTURE; CHEMICALLY INDUCED; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85040177178     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13176     Document Type: Article

References (13)

1. Nicodemus KK, Folsom AR. Iowa Women's Health Stdy type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24:1192-1197.
2. Nirantharakumar K, Toulis KA, Wijesinghe H, et al. Impact of diabetes on inpatient mortality and length of stay for elderly patients presenting with fracture of the proximal femur. J Diabetes Complications. 2013;27:208-210.
3. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44-51.
4. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157-166.
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
6. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971.
7. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990-999.
8. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159-169.
9. Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in THIN database. J Clin Endocrinol Metab. 2017;102:1719-1725.
10. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32-39.
11. Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nystrom T, Norhammar A. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract. 2016;117:39-47.
12. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8-10.
13. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739-1744.